, Tracking Stock Market Picks
Enter Symbol:
BioLineRx, Ltd. (BLRX) [hlAlert]

BioLineRx, Ltd. operates as a clinical-stage biopharmaceutical development company worldwide. Its clinical therapeutic candidates under development include BL-1020, a Phase IIb completed product for the treatment of schizophrenia; BL-1040, a Phase I/II clinical trial completed medical device developed for the prevention of cardiac remodeling in acute myocardial infarction
patients; and BL-5010, a novel formulation under Phase I/II clinical trial for non surgical removal of skin lesions. The company?s product pipeline under pre-clinical stage of development includes BL-1021 for neuropathic pain; BL-2030 for autoimmune diseases; BL-4010 for cancer tumors; BL-4040 for acute kidney failure; BL-5030 for thromboembolic diseases; BL-5040 for inflammatory diseases and pathological weight loss; BL-6010 for type II diabetes; BL-6020 for cancer cachexia; and BL-6030 for bacterial biofilm. It also operates a biotechnology incubator to evaluate and develop pre-clinical therapeutic candidates. The company was founded in 2003 and is based in Jerusalem, Israel.
( Total: 3 Current Stock Recommendations )
BioLineRx, Ltd.   (3)
Buy 100%
Related companies

Date (ET)MemberRatingYTD

* As of 8/27/2015 12:00 AM
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy